Navigation Links
First new C. difficile drug in a generation superior to existing treatments: Researchers
Date:2/2/2011

This release is available in French.

Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment. Their results were published in February, 2011 in The New England Journal of Medicine.

"There wasn't much interest in C. difficile for many years, because it wasn't considered a serious disease," said study co-author Dr. Mark A. Miller, head of the Division of Infectious Diseases and Chief of Microbiology at the Jewish General Hospital in Montreal, and a clinical investigator at the Lady Davis Institute for Medical Research. "However, over the past decade the bacterium has mutated into something much more serious that has caused epidemics worldwide. It is particularly notorious for recurrences. About 20 to 30 percent of patients suffer relapses. Recurrent C. difficile is very difficult to treat, and this has spurred interest in newer and better treatments."

Fidaxomicin, developed by Optimer Pharmaceuticals of San Diego, is the first in a new class of narrow-spectrum macrocyclic antibiotics. It is only minimally absorbed from the gut into the bloodstream and is specifically targeted at C. difficile in the intestine. Thus the drug acts by killing C. difficile bacteria without affecting the beneficial flora in the human gut which help stave off recurrences.

A total of 629 patients were enrolled in the multicentre, double-blind, randomized, parallel-group trial conducted between May 9, 2006, and August 21, 2008. They
'/>"/>

Contact: Mark Shainblum
mshainblum@jgh.mcgill.ca
514-340-8222 x6592
Jewish General Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. First study of dispersants in Gulf spill suggests a prolonged deepwater fate
2. For robust robots, let them be babies first
3. New technology provides first view of DNA damage within entire human genome
4. In scientific first, researchers visualize naturally occurring mRNA
5. UF study of lice DNA shows humans first wore clothes 170,000 years ago
6. U of Minnesota center releases nations first long-term framework for statewide water sustainability
7. First come, first served?
8. Longevinex exhibits L-shaped safety curve for first time in resveratrol biology
9. Experts converge at Arizona State University for first preventive cancer vaccine conference
10. Hoyos Corporation Rolls Out First Iris-Biometrics System Priced to Compete with Generic Card Readers
11. Metabolism models may explain why Alzheimers disease kills some neuron types first
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
(Date:9/29/2014)... of gut bacteria called Clostridium ramosum , coupled with ... work is published this week in mBio , the ... , A research team from the German Institute of Human ... bacteria including C. ramosum gained weight when fed ... ramosum were less obese even when consuming a high-fat ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... State University doctoral student Jennifer Smith has shed new light ... importantly hunt for their food alone. In a ... Smith, a student in MSU,s Department of Zoology, shows that ... large, cooperative societies, they also realize that venturing on their ...
... terranes comprise a huge portion of real estate in ... containing rocks and fossils very different from those in ... mixed rocks, tectonic styles, metamorphism, and volcanic origins, much ... puzzle, this new Geological Society of America Special Paper ...
... to purchase a powerful $2 million computer that will ... diagnose and treat brain disease, heart illnesses, cancer and ... Medicine, based at Johns Hopkins, Homewood campus in Baltimore, ... for 2008 awarded by the National Center for Research ...
Cached Biology News:Spotted hyenas can increase survival rates by hunting alone 2$2 million computer will help unravel major medical ailments 2$2 million computer will help unravel major medical ailments 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., ... discovery and development of proprietary new molecular entity ... Patent and Trademark Office (USPTO) issued U.S. Patent ... entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl ... Making and Use Thereof." The patent, ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2Global Next-generation Sequencing Trends 2
... microRNA Technology Submitted for, Regulatory Approval to the New York State Department of ... University ... ... Two Additional microRNA-Related Patents Allowed, REHOVOT, Israel and ...
... 21 Daiichi Sankyo Co., Ltd. announced today,that it ... held firm,U3 Pharma AG, a German biotechnology company focusing ... Daiichi Sankyo will purchase 100 percent of the stock ... million dollars) for the,company. Closure of the transaction is ...
... May 20 NASA has,developed a revolutionary nanotechnology-based ... viruses and parasites. This biosensor,will be used to ... in,water, food and other contaminated sources., NASA,s ... licensed the,biosensor technology to Early Warning Inc., Troy, ...
Cached Biology Technology:Rosetta Genomics Reports First Quarter 2008 Financial Results 2Rosetta Genomics Reports First Quarter 2008 Financial Results 3Rosetta Genomics Reports First Quarter 2008 Financial Results 4Rosetta Genomics Reports First Quarter 2008 Financial Results 5Rosetta Genomics Reports First Quarter 2008 Financial Results 6Rosetta Genomics Reports First Quarter 2008 Financial Results 7Rosetta Genomics Reports First Quarter 2008 Financial Results 8Rosetta Genomics Reports First Quarter 2008 Financial Results 9Rosetta Genomics Reports First Quarter 2008 Financial Results 10Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3NASA Nanotechnology-Based Biosensor Helps Detect Biohazards 2
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... minor groove-binding probe for DNA. Binds to ... to AT rich DNA), forming a stable ... than DAPI alone. DAPI is several times ... DNA in agarose gels. It may be ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Biology Products: